

COMPANY OVERVIEW

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. We have identified promising preclinical and clinical-stage antiviral therapeutics that target the replication process of influenza virus, norovirus, coronavirus and hepatitis C virus.

RECENT NEWS

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment

Sep 8 2025, 8:00 AM EDT

Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference

Sep 3 2025, 8:00 AM EDT

Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Aug 14 2025, 8:00 AM EDT

STOCK OVERVIEW

Symbol	COCP
Exchange	Nasdaq
Market Cap	14.88m
Last Price	\$1.45
52-Week Range	\$1.12 - \$3.26

09/09/2025 08:00 PM EDT

INVESTOR RELATIONS

Alliance Advisors IR
Jody Cain
T: 310-691-7100
jcain@allianceadvisors.com

MANAGEMENT TEAM

Sam Lee, Ph.D.

Co-Chief Executive Officer and President

James J. Martin

Co-Chief Executive Officer and Chief Financial Officer

COCRYSTAL PHARMA, INC.

19805 North Creek Parkway
Bothell, WA 98011
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.